Join the Conference Call for Q3 Financial Results
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is gearing up to host a detailed conference call where executives will delve into their financial performance for the third quarter of 2025. This event is set to take place on Thursday, October 30, 2025, at 8:30 a.m. ET. Investors and stakeholders are encouraged to be part of this important discussion.
Accessing the Event
The conference call will be accessible in real-time by phone for those who pre-register. In addition to the phone call, a live audio webcast will also be available. Interested parties can find access to the webcast along with accompanying slides on the "Events and Presentations" page of the "Investors and Media" section of the Apellis Pharmaceuticals website. For those unable to attend live, a replay of the webcast will remain available for 90 days after the event, ensuring that all stakeholders have the chance to stay informed.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals is a pioneering biopharmaceutical organization dedicated to improving healthcare through groundbreaking advancements in complement science. The company has successfully ushered in the first new class of complement medicine in over fifteen years. They currently have two C3-targeting therapies approved, which treat four serious diseases.
Innovative Treatments
Their significant breakthroughs include the introduction of the first-ever therapy specifically designed for geographic atrophy, a primary contributor to blindness. Additionally, they have created the first treatment option for patients aged 12 and older suffering from C3G or primary IC-MPGN, both rare but severe kidney disorders. Apellis believes their journey has only begun, and they are committed to unlocking the vast potential that targeting C3 can offer across many serious diseases.
Investor Relations and Contact
For more detailed information or inquiries, the point of contact is Eva Stroynowski, who can be reached via email at eva.stroynowski@apellis.com or by phone at 617.938.6229. Apellis Pharmaceuticals values transparency and encourages all interested parties to connect for further insights into their innovative therapies and future directions.
Staying Connected with Apellis
Stay informed about Apellis Pharmaceuticals and its developments by visiting their official website and following them on social media platforms. Keeping up with their ongoing projects and the impact of their therapies in the biotech landscape can provide significant insights into the future of healthcare.
Frequently Asked Questions
What is the date of the conference call?
The conference call is scheduled for October 30, 2025, at 8:30 a.m. ET.
How can I access the conference call?
Participants can pre-register to access the call via phone, and a live audio webcast will also be available through the company’s website.
Who should I contact for investor relations?
For investor inquiries, you can reach Eva Stroynowski at eva.stroynowski@apellis.com.
What is Apellis Pharmaceuticals known for?
Apellis is recognized for its innovative therapies targeting complement science, successfully treating serious diseases such as geographic atrophy and rare kidney conditions.
Is there a replay available for the conference call?
Yes, a replay of the conference call will be available for 90 days following the event.
